ImmunityBio, Inc. (IBRX)
10.28
+1.00
(+10.83%)
USD |
NASDAQ |
Oct 02, 16:00
10.30
+0.02
(+0.15%)
After-Hours: 20:00
ImmunityBio Gross Profit Margin (Quarterly) : 90.82% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 90.82% |
| March 31, 2026 | 89.55% |
| December 31, 2025 | 88.91% |
| September 30, 2025 | 87.12% |
| June 30, 2025 | 84.80% |
| March 31, 2025 | 76.47% |
| December 31, 2024 | 45.21% |
| September 30, 2024 | 27.04% |
| June 30, 2024 | -320.8% |
| March 31, 2024 | -11.29K% |
| December 31, 2023 | -3.18K% |
| September 30, 2023 | -5.49K% |
| June 30, 2023 | -15.31K% |
| March 31, 2023 | -1.64K% |
| December 31, 2022 | -9.32K% |
| September 30, 2022 | -4.96K% |
| June 30, 2022 | -16.85K% |
| March 31, 2022 | -38.53K% |
| December 31, 2021 | 0.00% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 0.00% |
| December 31, 2020 | -10.60K% |
| September 30, 2020 | -3.43K% |
| Date | Value |
|---|---|
| June 30, 2020 | -226.6K% |
| March 31, 2020 | -10.46K% |
| December 31, 2019 | -24.44K% |
| September 30, 2019 | -18.25K% |
| June 30, 2019 | -9.21K% |
| March 31, 2019 | -60.28K% |
| December 31, 2018 | 0.00% |
| September 30, 2018 | 0.00% |
| June 30, 2018 | 0.00% |
| March 31, 2018 | 0.00% |
| December 31, 2017 | 0.00% |
| September 30, 2017 | 0.00% |
| June 30, 2017 | 0.00% |
| March 31, 2017 | 0.00% |
| December 31, 2016 | 0.00% |
| September 30, 2016 | 0.00% |
| June 30, 2016 | 0.00% |
| March 31, 2016 | 0.00% |
| December 31, 2015 | 0.00% |
| September 30, 2015 | 0.00% |
| June 30, 2015 | 0.00% |
| March 31, 2015 | 50.00% |
| December 31, 2014 | 0.00% |
| March 31, 2014 | 57.34% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Moderna, Inc. | -7.59% |
| Sarepta Therapeutics, Inc. | 60.18% |
| Arrowhead Pharmaceuticals, Inc. | 91.15% |
| Oncolytics Biotech, Inc. | -- |
| Sangamo Therapeutics, Inc. | 39.18% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -183.9% |
| Return on Invested Capital | -356.0% |
| Profit Margin (Quarterly) | -449.6% |
| Operating Margin (Quarterly) | -120.4% |
| Return on Net Operating Assets | -431.9% |